A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

  • sponsor
    Incyte Corporation
Updated on 8 December 2020
stem cell transplantation
bone marrow transplant
transplant conditioning
stem cell transplant
nutritional supplement


A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease


This is an open-label, single-cohort, multicenter Phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory Grades II to IV acute GVHD.

Study Start Date: November 2016
Estimated Study Completion Date: June 2020
Estimated Primary Completion Date: March 2020

Condition Bone marrow transplant, Bone marrow transplant, Stem Cell Transplant
Clinical Study IdentifierTX146567
SponsorIncyte Corporation
Last Modified on8 December 2020


Yes No Not Sure

Inclusion Criteria

Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies. Recipients of nonmyeloablative and myeloablative conditioning regimens are eligible
Clinically suspected Grades IIB to IVD acute GVHD as per Minnesota-Center for International Blood and Marrow Transplant Research (MN-CIBMTR) criteria, occurring after allo-HSCT with any conditioning regimen and any anti-GVHD prophylactic program
Subjects with steroid-refractory acute GVHD, defined as any of the following
Subjects with progressive GVHD (ie, increase in stage in any organ system or any new organ involvement) after 3 days of primary treatment with methylprednisolone = 2 mg/kg per day (or equivalent)
Subjects with GVHD that has not improved (ie, decrease in stage in at least 1 involved organ system) after 7 days of primary treatment with methylprednisolone = 2 mg/kg per day (or equivalent)
Subjects who previously began corticosteroid therapy at a lower dose (at least 1 mg/kg per day methylprednisolone) but develop new GVHD in another organ system
Subjects who cannot tolerate a corticosteroid taper, that is, begin corticosteroids at 2.0 mg/kg per day, demonstrate response, but progress before a 50% decrease from the initial starting dose of corticosteroids is achieved
Evidence of myeloid engraftment (eg, absolute neutrophil count = 1.0 × 109/L for 3 consecutive days if ablative therapy was previously used). Use of growth factor supplementation is allowed
Evidence of platelet engraftment (ie, platelets = 20 × 109/L)
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3

Exclusion Criteria

Has received more than 1 allo-HSCT
Has received more than 1 systemic treatment in addition to corticosteroids for acute GVHD
Presence of GVHD overlap syndrome as per NIH guidelines
Presence of an active uncontrolled infection. An active uncontrolled infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection. Persisting fever without signs or symptoms will not be interpreted as an active uncontrolled infection
Known human immunodeficiency virus infection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note